These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6714285)

  • 21. Dose proportionality of nadolol pharmacokinetics after intravenous administration to healthy subjects.
    Morrison RA; Singhvi SM; Creasey WA; Willard DA
    Eur J Clin Pharmacol; 1988; 33(6):625-8. PubMed ID: 3366166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and metabolism of a new beta-adrenergic blocking agent, the 1, ter-butyl-amino-3-(1,2,3,4-tetrahydro-1,4-ethano-8-hydroxy-5-naphthoxy)-2-propanol (K 5407).
    Goldaniga G; Montesanti L; Pianezzola E; Valzelli G
    Eur J Drug Metab Pharmacokinet; 1980; 5(1):9-20. PubMed ID: 6104601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and absolute bioavailability of carteolol, a new beta-adrenergic receptor blocking agent.
    Ishizaki T; Ohnishi A; Sasaki T; Kushida K; Horai Y; Chiba K; Suganuma T
    Eur J Clin Pharmacol; 1983; 25(1):95-101. PubMed ID: 6137389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of carteolol in relation to renal function.
    Hasenfuss G; Schäfer-Korting M; Knauf H; Mutschler E; Just H
    Eur J Clin Pharmacol; 1985; 29(4):461-5. PubMed ID: 4092726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of oral talinolol following a single dose and during steady state in patients with chronic renal failure and healthy volunteers.
    Krueger M; Achenbach H; Terhaag B; Haase H; Richter K; Oertel R; Preiss R
    Int J Clin Pharmacol Ther; 2001 Feb; 39(2):61-6. PubMed ID: 11270803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of metoprolol in patients with hepatic cirrhosis.
    Regårdh CG; Jordö L; Ervik M; Lundborg P; Olsson R; Rönn O
    Clin Pharmacokinet; 1981; 6(5):375-88. PubMed ID: 7333059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Kinetics of pamatolol, a cardioselective beta adrenoreceptor blocker.
    Carruthers SG; Pentikainen P; Hosler JP; Azarnoff DL
    Clin Pharmacol Ther; 1979 Dec; 26(6):682-5. PubMed ID: 40725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of betaxolol in middle aged patients.
    Bianchetti G; Thiercelin JF; Thenot JP
    Eur J Clin Pharmacol; 1986; 31(2):231-3. PubMed ID: 2879735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The pharmacokinetics of the prolonged-action beta-adrenoblocker nadolol in hypertension patients after a single administration].
    Poteshnykh AV; Piotrovskiĭ VK; Metelitsa VI; Filatova NP; Ostrovskaia TP
    Eksp Klin Farmakol; 1992; 55(3):47-50. PubMed ID: 1458164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of metipranolol in normal man.
    Abshagen U; Betzien G; Kaufmann B; Endele G
    Eur J Clin Pharmacol; 1982; 21(4):293-301. PubMed ID: 6120080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. beta-2 Adrenergic blockade evaluated with epinephrine after placebo, atenolol, and nadolol.
    Hiatt WR; Wolfel EE; Stoll S; Nies AS; Zerbe GO; Brammell HL; Horwitz LD
    Clin Pharmacol Ther; 1985 Jan; 37(1):2-6. PubMed ID: 2856902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comment on the comment on nadolol article.
    Drug Intell Clin Pharm; 1981; 15(7-8):603. PubMed ID: 6113946
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacokinetic and pharmacodynamic interaction of nadolol with itraconazole, rifampicin and grapefruit juice in healthy volunteers.
    Misaka S; Miyazaki N; Yatabe MS; Ono T; Shikama Y; Fukushima T; Kimura J
    J Clin Pharmacol; 2013 Jul; 53(7):738-45. PubMed ID: 23677858
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of propranolol and nadolol pharmacokinetics and clinical effects in thyrotoxicosis.
    Wilkinson R; Burr WA
    Am Heart J; 1984 Oct; 108(4 Pt 2):1160-7. PubMed ID: 6148879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Separate and combined effects of nadolol and nifedipine on the cardiac response to exercise.
    Wilkins MR; Woods KL; Jack DB; Kendall MJ; Laugher SJ
    Eur J Clin Pharmacol; 1985; 28(2):113-7. PubMed ID: 3987793
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of atenolol in hypertensive subjects with and without co-administration of chlorthalidone.
    Riva E; Farina PL; Sega R; Tognoni G; Bastain W; McAinsh J
    Eur J Clin Pharmacol; 1980 May; 17(5):333-7. PubMed ID: 7418712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On the pharmacokinetics of talinolol, a new beta 1-receptor blocking agent.
    Haustein KO; Fritzsche K
    Int J Clin Pharmacol Ther Toxicol; 1981 Sep; 19(9):392-5. PubMed ID: 6117520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absolute bioavailability study in the dog with Visacor, a new cardioselective beta blocking drug with intrinsic sympathomimetic activity.
    McAinsh J; Smith RP; Ferguson RA
    Eur J Drug Metab Pharmacokinet; 1984; 9(2):129-39. PubMed ID: 6146530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kinetics and absolute bioavailability of atenolol.
    Mason WD; Winer N; Kochak G; Cohen I; Bell R
    Clin Pharmacol Ther; 1979 Apr; 25(4):408-15. PubMed ID: 428185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical pharmacokinetics and metabolism of bevantolol.
    Latts JR
    Angiology; 1986 Mar; 37(3 Pt 2):221-5. PubMed ID: 2871781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.